Navigation Links
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
Date:12/9/2013

The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

It is estimated that approximately 160 million individuals, i.e. 2.35% of the world's population, are chronically infected with HCV. In the European Union alone, between 7.3 and 8.8 million people are infected with HCV, double the previous estimate made in 1997. The prevalence varies across the region with higher rates seen in the south and the east, making HCV a critical area of attention for hepatologists as one fifth of HCV-infected patients are at risk of developing cirrhosis or liver cancer (2).

HCV CPG co-chair reviewer and consultant hepatologist at Queen Elizabeth Hospital, Birmingham, Professor David Mutimer said: "As our understanding of HCV increases and therapies evolve, more complex treatment strategies are necessary to achieve the primary goal of curing the infection.

"Since EASL published the last HCV CPG in 2011, two protease inhibitors have been approved for use in patients infected with HCV genotype 1. These first-generation direct-acting antivirals are the first of many direct acting antiviral drugs which will revolutionise treatment for HCV patients, including those who failed to respond to previous therapies. The new guidelines provide essential information on the recommended use of these newly licensed drugs to help prescribers deliver optimal care for their HCV patients."

Based on a systematic review of existing literature, the CPGs provide best practice recommendations on a number of key areas:

  • Current standard of care and developing therapies
  • Diagnosis of acute and chronic hepatitis C
  • Goals and endpoints of HCV therapy
  • Indications for treatment and who should be treated
  • Treatment strategies for different viral genotypes
  • Treatment monitoring including virological response-guided triple, and dual therapy
  • Monitoring treatment safety
  • Treatment of special groups including HIV co-infection, hepatitis B co-infection and patients with other co-morbidities such as severe liver disease

The guidelines also contain significant discussion about people who inject drugs (PWID*) providing an overview of the published literature relating to the treatment of these patients, and covering issues such as:

  • Re-infection following successful HCV treatment in patients at high risk (such as PWID)
  • The burden of chronic HCV and advanced liver disease among ageing cohorts of PWID

Professor Mutimer added: "With HCV spread among PWID now accounting for the vast majority of incident cases in developed countries, and with modelling studies suggesting that treatment for PWID could reduce transmission, it is critical that physicians review and adopt these guidelines when managing this important group of patients."

Commenting on the CPGs, EASL Secretary General Professor Markus Peck-Radosavljevic said "EASL is dedicated to promoting hepatology research and education to improve the worldwide treatment of liver disease. As treatment for hepatitis C continues to progress rapidly with the development and approval of new therapies, it's vital to ensure that our series of Clinical Practice Guidelines reflect best practice to drive better clinical outcomes.

"As there have been several key clinical and scientific advances over the past two years, these guidelines build upon the recommendations reported by the EASL HCV panel of experts in 2011. EASL encourage clinicians to refer to these new HCV guidelines for the most up-to-date, evidence based methods to offer patients first class treatment."


'/>"/>

Contact: Courtney Lock
easlpressoffice@cohnwolfe.com
44-207-331-5317
European Association for the Study of the Liver
Source:Eurekalert  

Related biology news :

1. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
2. Elseviers Maturitas publishes position statement on fertility preservation
3. Genetics in Medicine publishes special issue dedicated to genomics in electronic health records
4. Journal of Spinal Cord Medicine publishes special issue on assistive technology
5. American Academy of Microbiology publishes West Nile virus report
6. Reproductive BioMedicine Online publishes study on assisted reproduction
7. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
8. Leading RSV researcher publishes work at Le Bonheur Childrens
9. PeerJ publishes its first articles
10. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
11. Professor publishes on first-ever imaging of cells growing on spherical surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), a ... will open a state-of-the-art bioinformatics lab, using ,big data, ... announcement comes as Liz Scott , co-executive director ... Moonshot Summit in Washington, D.C. , ... participant and advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
Breaking Biology Technology: